AAAAAA

   
Results: 1-13 |
Results: 13
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients withosteoarthritis
Authors: Truitt, KE Sperling, RS Ettinger, WH Greenwald, M DeTora, L Zeng, Q Bolognese, J Ehrich, E
Citation: Ke. Truitt et al., A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients withosteoarthritis, AGING-CLIN, 13(2), 2001, pp. 112-121
Clinical improvement in osteoarthritis - Reply
Authors: Ehrich, E Davies, G Watson, D Bolognese, J Seidenberg, B Bellamy, N
Citation: E. Ehrich et al., Clinical improvement in osteoarthritis - Reply, J RHEUMATOL, 28(8), 2001, pp. 1932-1932
Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors
Authors: Detora, LM Krupa, D Bolognese, J Sperling, RS Ehrich, EW
Citation: Lm. Detora et al., Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors, J RHEUMATOL, 28(11), 2001, pp. 2494-2503
Assessment of equivalence on multiple endpoints
Authors: Quan, H Bolognese, J Yuan, WY
Citation: H. Quan et al., Assessment of equivalence on multiple endpoints, STAT MED, 20(21), 2001, pp. 3159-3173
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs - A 6-week and a 1-year trial in patients with osteoarthritis
Authors: Saag, K van der Heijde, D Fisher, C Samara, A DeTora, L Bolognese, J Sperling, R Daniels, B
Citation: K. Saag et al., Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs - A 6-week and a 1-year trial in patients with osteoarthritis, ARCH FAM M, 9(10), 2000, pp. 1124-1134
COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin
Authors: Sigthorsson, G Crane, R Simon, T Hoover, M Quan, H Bolognese, J Bjarnason, I
Citation: G. Sigthorsson et al., COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin, GUT, 47(4), 2000, pp. 527-532
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
Authors: Cannon, GW Caldwell, JR Holt, P McLean, B Seidenberg, B Bolognese, J Ehrich, E Mukhopadhyay, S Daniels, B
Citation: Gw. Cannon et al., Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip, ARTH RHEUM, 43(5), 2000, pp. 978-987
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis - A randomized, double-blind, placebo-controlled trial
Authors: Hawkey, C Laine, L Simon, T Beaulieu, A Maldonado-Cocco, J Acevedo, E Shahane, A Quan, H Bolognese, J Mortensen, E
Citation: C. Hawkey et al., Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis - A randomized, double-blind, placebo-controlled trial, ARTH RHEUM, 43(2), 2000, pp. 370-377
A randomized trial of the efficacy and tolerability of the COX-2 inhibitorrofecoxib vs ibuprofen in patients with osteoarthritis
Authors: Day, R Morrison, B Luza, A Castaneda, O Strusberg, A Nahir, M Helgetveit, KB Kress, B Daniels, B Bolognese, J Krupa, D Seidenberg, B Ehrich, E
Citation: R. Day et al., A randomized trial of the efficacy and tolerability of the COX-2 inhibitorrofecoxib vs ibuprofen in patients with osteoarthritis, ARCH IN MED, 160(12), 2000, pp. 1781-1787
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults
Authors: Murphy, MG Bach, MA Plotkin, D Bolognese, J Ng, J Krupa, D Cerchio, K Gertz, BJ
Citation: Mg. Murphy et al., Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults, J BONE MIN, 14(7), 1999, pp. 1182-1188
Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
Authors: Ehrich, EW Schnitzer, TJ McIlwain, H Levy, R Wolfe, F Weisman, M Zeng, Q Morrison, B Bolognese, J Seidenberg, B Gertz, BJ
Citation: Ew. Ehrich et al., Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib, J RHEUMATOL, 26(11), 1999, pp. 2438-2447
The safety profile, tolerability, and effective dose range of rofecoxib inthe treatment of rheumatoid arthritis
Authors: Schnitzer, TJ Truitt, K Fleischmann, R Dalgin, P Block, J Zeng, Q Bolognese, J Seidenberg, B Ehrich, EW
Citation: Tj. Schnitzer et al., The safety profile, tolerability, and effective dose range of rofecoxib inthe treatment of rheumatoid arthritis, CLIN THER, 21(10), 1999, pp. 1688-1702
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucose of patients with osteoarthritis
Authors: Laine, L Harper, S Simon, T Bath, R Johanson, J Schwartz, H Stern, S Quan, H Bolognese, J
Citation: L. Laine et al., A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucose of patients with osteoarthritis, GASTROENTY, 117(4), 1999, pp. 776-783
Risultati: 1-13 |